GBSciences, Inc.

12/18/2023

Yesterday, Gb Sciences was featured on Worldwide Business with kathy ireland® to discuss our plant-inspired medicines including a successful dose-response study for the cannabinoid-containing Parkinson’s disease medication. Click the link below to view the segment.

GB Sciences featured on Worldwide Business with kathy ireland® to discuss new drug for Parkinson's Disease. To learn more visit, https://www.gbsciences.com.

12/14/2023

We are excited to share that our novel Parkinson's disease medication will be featured on Worldwide Business with kathy ireland® this Sunday, December 17th at 4 ET. Please tune in to see our President and Chief Science Officer Andrea Small-Howard, PhD, MBA discuss our successful dose response study for our cannabinoid-based therapy for Parkinson’s disease.

Read more at this link:

Tune in this Sunday, Dec. 17, at 5:30 p.m. ET on the Fox Business Network to learn about Gb Sciences’ cannabinoid-based medicine for the treatment of Parkinson’s disease.

07/11/2023

GB Sciences, Inc is developing a first-in-class, cannabinoid-based treatment for the motor symptoms of Parkinson's disease. From this critical study performed at The University of Lethbridge, we have established ranges for the dosage and duration of action in a rodent model that helps us to predict the corresponding and appropriate dose range and duration of action of Gb Sciences' Parkinson's disease therapies for our first-in-human trial.

The Parkinson's disease market is expected to grow to $12.8 billion by 2028.

03/20/2023

03/20/2023

Patent Update: Our first international patent protecting our proprietary cannabinoid-based formulations for Parkinson's Disease has been issued in China. This is a major milestone for our intellectual property strategy, proving our formulations can work globally and strengthening our overall patent portfolio. Read the full press release update here:

According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.

01/10/2023

Our President & Chief Science Officer, Andrea Small-Howard, was invited back to Stock Day Podcast to discuss how Gb Sciences is looking to re-invent the future of medicine in 2023 through the use of plant-inspired medicines and our proprietary technology. Listen to the full episode here:

December 27 2022 GB Sciences, Inc. President & Chief Science Officer, Dr. Andrea Small-Howard, is Featured On The Stock Day Podcast Alexandria LeBlanc Cannabis Corner GBLX Dec 27th, 2022 To listen to the interview with Dr. Andrea Small-Howard, please click the link below:

01/03/2023

Thank you Benzinga for sharing our recent white paper that discussed how we are developing anti-inflammatory, cannabinoid-based therapeutics to help combat viral infections in the future. Read more:

GB Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired, biopharmaceutical R & D development company recently published a study that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation.

12/12/2022

At Gb Sciences, we are invested in developing plant-inspired medications to help those who are struggling with anxiety and depression. Using our PhAROS AI-enabled drug discovery technology, we formulated kava-based medicines for the treatment of these common mental health disorders. Our most recent preclinical results have shown potential for future pharmaceutical use. Learn more about the study here:

As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychedelic companies.

10/18/2022

Our President and CSO, Dr. Andrea Small-Howard, was invited onto the IDC Podcast with Kevin Stevenson hosted by MarketScale TV, to discuss the steps Gb Sciences is taking to bring medicines to market faster through analytics and machine learning. Our mission is to use science to unlock the potential of the cannabinoid plant using our own proprietary AI software. Watch or listen: https://marketscale.com/shows/i-dont-care/ #

I Don't Care with Kevin Stevenson is a podcast produced by MarketScale that tackles the biggest trends and topics in healthcare.

10/13/2022

Our President & CSO, Dr. Andrea Small-Howard, is speaking today at the Canna Pharma 2022 conference in San Diego, CA. Her session, titled "Case Studies: Identification of Minimum Essential Therapeutic Mixtures from Cannabis Plant Extracts by Screening in Cell and Animal Models" will highlight Gb Sciences' novel process for developing disease-specific, cannabinoid-based therapeutics.
https://gbsciences.newswire.com/news/today-gb-sciences-president-demonstrates-effectiveness-of-simplified-21841107

10/10/2022

Gb Sciences has co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of our proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson’s disease (PD). This study positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics. Learn more:

As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms

09/06/2022

Today for the second time, Gb Sciences' drug development progress was featured in an article in Pharma's Almanac. The Q&A with our President Andrea Small-Howard, describes recent successes with preparing our lead Parkinson's disease formulations for clinical trials, new data validating the efficacy of our anxiety formulations, and the demonstration of improved stability of our oral chronic pain medicines. Read the full article here:

Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chron...